How Analysts Feel About Galectin Therapeutics Incorporated (NASDAQ:GALT) After Increase in Sellers?

January 19, 2018 - By Linda Rogers

 How Analysts Feel About Galectin Therapeutics Incorporated (NASDAQ:GALT) After Increase in Sellers?

Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It worsened, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Geode Mgmt accumulated 0% or 195,411 shares. Schwab Charles Invest has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Natl Bank Of New York Mellon Corp reported 22,121 shares. Thrivent Fincl For Lutherans holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 6,000 shares. Cutter Brokerage holds 0.05% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 54,600 shares. The Arizona-based Tci Wealth Advsrs has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Guggenheim Capital Ltd Liability holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 11,688 shares. Courage Mngmt Llc, a Tennessee-based fund reported 130,000 shares. Dynamic Advsr Solutions Limited Liability owns 10,000 shares or 0.01% of their US portfolio. Northern Tru has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Pennsylvania-based Susquehanna Gru Llp has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Tiedemann Wealth Lc holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 15,000 shares. Vanguard Grp reported 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). The New York-based Benchmark Advisors has invested 0.32% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne French Llp Mi holds 30,500 shares.

The stock of Galectin Therapeutics Incorporated (NASDAQ:GALT) registered an increase of 18.01% in short interest. GALT’s total short interest was 1.29M shares in January as published by FINRA. Its up 18.01% from 1.09 million shares, reported previously. With 334,200 shares average volume, it will take short sellers 4 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Incorporated’s float is 5.15%.

The stock decreased 3.96% or $0.23 during the last trading session, reaching $5.58. About 545,569 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since January 19, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $201.65 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. As per Wednesday, September 28, the company rating was downgraded by TH Capital. FBR Capital downgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Monday, October 3. FBR Capital has “Mkt Perform” rating and $2 target. H.C. Wainwright reinitiated Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Monday, March 28. H.C. Wainwright has “Buy” rating and $8 target. The firm has “Neutral” rating given on Thursday, September 29 by H.C. Wainwright. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, December 7 with “Buy” rating. H.C. Wainwright upgraded the shares of GALT in report on Thursday, March 30 to “Buy” rating. The rating was maintained by Roth Capital on Thursday, January 4 with “Buy”. The rating was initiated by H.C. Wainwright on Monday, September 21 with “Buy”. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Wednesday, June 14. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Sell” rating by Roth Capital on Wednesday, September 28.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Zacks.com which released: “Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1% December 28, 2017” on December 28, 2017. Also Prnewswire.com published the news titled: “Technical Perspectives on Generic Drugs Stocks — Fibrocell Science, Galectin …” on January 19, 2018. Seekingalpha.com‘s news article titled: “Galectin Therapeutics Is On To Something Big” with publication date: January 07, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: